[HTML][HTML] Novel anticoagulants versus vitamin K antagonists for cardioversion of non-valvular atrial fibrillation–a meta-analysis of more than 17000 patients
Non-vitamin K antagonist oral anticoagulants (NOACs) have proven a favorable risk-benefit
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
[HTML][HTML] Novel anticoagulants versus vitamin K antagonists for cardioversion of non-valvular atrial fibrillation–a meta-analysis of more than 17000 patients
RI Mincu, AA Mahabadi, M Totzeck, T Rassaf - Scientific Reports, 2019 - ncbi.nlm.nih.gov
Non-vitamin K antagonist oral anticoagulants (NOACs) have proven a favorable risk-benefit
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
Novel anticoagulants versus vitamin K antagonists for cardioversion of non-valvular atrial fibrillation-a meta-analysis of more than 17000 patients
RI Mincu, AA Mahabadi, M Totzeck… - Scientific …, 2019 - ui.adsabs.harvard.edu
Non-vitamin K antagonist oral anticoagulants (NOACs) have proven a favorable risk-benefit
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
Novel anticoagulants versus vitamin K antagonists for cardioversion of non-valvular atrial fibrillation-a meta-analysis of more than 17000 patients.
RI Mincu, AA Mahabadi, M Totzeck, T Rassaf - Scientific Reports, 2019 - europepmc.org
Non-vitamin K antagonist oral anticoagulants (NOACs) have proven a favorable risk-benefit
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
Novel anticoagulants versus vitamin K antagonists for cardioversion of non-valvular atrial fibrillation-a meta-analysis of more than 17000 patients
RI Mincu, AA Mahabadi, M Totzeck… - Scientific …, 2019 - pubmed.ncbi.nlm.nih.gov
Non-vitamin K antagonist oral anticoagulants (NOACs) have proven a favorable risk-benefit
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
[引用][C] Novel anticoagulants versus vitamin K antagonists for cardioversion of non-valvular atrial fibrillation–a meta-analysis of more than 17000 patients
RI Mincu, AA Mahabadi, M Totzeck, T Rassaf - Scientific Reports, 2019 - elibrary.ru
Novel anticoagulants versus vitamin K antagonists for cardioversion of non-valvular atrial fibrillation-a meta-analysis of more than 17000 patients.
RI Mincu, AA Mahabadi, M Totzeck, T Rassaf - Scientific Reports, 2019 - europepmc.org
Non-vitamin K antagonist oral anticoagulants (NOACs) have proven a favorable risk-benefit
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …